# Rapid Micro Biosystems, Inc.: overview
RPID · Nasdaq · CIK 1380106 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31
Pages: [Overview](/companies/rpid.md) · [Financials](/companies/rpid/financials.md) · [Filings](/companies/rpid/filings.md) · [Insiders](/companies/rpid/insiders.md)
Latest reported revenue: [$8.1m](/filings/0001380106-26-000101.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001380106-26-000101).
## Last eight quarters
| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [7.6](/filings/0001380106-25-000200.md) | [8.2 d](/filings/0001380106-26-000034.md) | [7.2](/filings/0001380106-26-000075.md) | [7.3](/filings/0001380106-26-000101.md) | [7.8](/filings/0001380106-25-000200.md) | [11.3 d](/filings/0001380106-26-000034.md) | [8.0](/filings/0001380106-26-000075.md) | [8.1](/filings/0001380106-26-000101.md) |
| Gross margin | % | not reported | not reported | [5.6%](/filings/0001380106-26-000075.md) | [3.8%](/filings/0001380106-26-000101.md) | not reported | not reported | [4.6%](/filings/0001380106-26-000075.md) | [15.0%](/filings/0001380106-26-000101.md) |
| Operating margin | % | [(158.3%)](/filings/0001380106-25-000200.md) | [(124.5%) d](/filings/0001380106-26-000034.md) | [(161.8%)](/filings/0001380106-26-000075.md) | [(167.3%)](/filings/0001380106-26-000101.md) | [(145.1%)](/filings/0001380106-25-000200.md) | [(108.2%) d](/filings/0001380106-26-000034.md) | [(173.1%)](/filings/0001380106-26-000075.md) | [(153.0%)](/filings/0001380106-26-000101.md) |
| Net margin | % | [(148.9%)](/filings/0001380106-25-000200.md) | [(117.6%) d](/filings/0001380106-26-000034.md) | [(156.3%)](/filings/0001380106-26-000101.md) | [(163.3%)](/filings/0001380106-26-000101.md) | [(146.8%)](/filings/0001380106-25-000200.md) | [(110.8%) d](/filings/0001380106-26-000034.md) | [(178.4%)](/filings/0001380106-26-000101.md) | [(160.5%)](/filings/0001380106-26-000101.md) |
| Diluted EPS | $ per share | [(0.26)](/filings/0001380106-25-000200.md) | not reported | [(0.26)](/filings/0001380106-26-000075.md) | [(0.27)](/filings/0001380106-26-000101.md) | [(0.26)](/filings/0001380106-25-000200.md) | not reported | [(0.31)](/filings/0001380106-26-000075.md) | [(0.27)](/filings/0001380106-26-000101.md) |
| Free cash flow | $m | [(8.8) d](/filings/0001380106-25-000200.md) | [(10.0) d](/filings/0001380106-26-000034.md) | [(9.4)](/filings/0001380106-26-000075.md) | [(10.1) d](/filings/0001380106-26-000101.md) | [(9.1) d](/filings/0001380106-25-000200.md) | [(3.3) d](/filings/0001380106-26-000034.md) | [(15.5)](/filings/0001380106-26-000075.md) | [(12.9) d](/filings/0001380106-26-000101.md) |
- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Gross profit: us-gaap:GrossProfit. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.
## Last five fiscal years
| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [23.2](/filings/0001380106-23-000016.md) | [17.1](/filings/0001380106-24-000073.md) | [22.5](/filings/0001380106-25-000058.md) | [28.1](/filings/0001380106-26-000034.md) | [33.6](/filings/0001380106-26-000034.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(203.3%)](/filings/0001380106-23-000016.md) | [(369.0%)](/filings/0001380106-24-000073.md) | [(251.2%)](/filings/0001380106-25-000058.md) | [(178.0%)](/filings/0001380106-26-000034.md) | [(141.1%)](/filings/0001380106-26-000034.md) |
| Net margin | % | [(316.5%)](/filings/0001380106-23-000016.md) | [(354.9%)](/filings/0001380106-24-000073.md) | [(233.0%)](/filings/0001380106-25-000058.md) | [(167.2%)](/filings/0001380106-26-000034.md) | [(140.3%)](/filings/0001380106-26-000034.md) |
| Diluted EPS | $ per share | [(3.94)](/filings/0001380106-23-000016.md) | [(1.43)](/filings/0001380106-24-000073.md) | [(1.22)](/filings/0001380106-25-000058.md) | [(1.08)](/filings/0001380106-26-000034.md) | [(1.05)](/filings/0001380106-26-000034.md) |
| Free cash flow | $m | [(58.2)](/filings/0001380106-23-000016.md) | [(65.3)](/filings/0001380106-24-000073.md) | [(46.9)](/filings/0001380106-25-000058.md) | [(45.5)](/filings/0001380106-26-000034.md) | [(31.9)](/filings/0001380106-26-000034.md) |
- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.
## Insider purchases and sales
The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/rpid/insiders.md)
None in coverage.
## Funds that report holding it
From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)
| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Bain Capital Life Sciences Investors, LLC](/funds/1703031.md) | 2026-06-30 | $14.6m | 8,434,560 | | Unchanged |
| [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $5.8m | 3,328,000 | | New +3,328,000 |
| [ABG-WTT Global Life Science Capital Partners GP Ltd](/funds/1832108.md) | 2026-06-30 | $3.2m | 1,848,296 | | Unchanged |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.7m | 982,034 | | Reduced −460 |
| [Evernest Financial Advisors, LLC](/funds/2009530.md) | 2026-06-30 | $875.4k | 506,000 | | Added +73,490 |
| [Advent International, L.P.](/funds/1034196.md) | 2026-06-30 | $657.0k | 379,794 | | Reduced −172,583 |
| [ESSEX INVESTMENT MANAGEMENT CO LLC](/funds/201772.md) | 2026-06-30 | $627.5k | 362,696 | | Reduced −521,235 |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $409.3k | 236,599 | | Reduced −46,681 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $394.7k | 228,041 | | Reduced −19,136 |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $366.9k | 212,101 | | Added +85,484 |
## Recent filings
[All 325 filings](/companies/rpid/filings.md)
| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-07 | 07:33 ET | [10-Q](/filings/0001380106-26-000101.md) | Quarterly report, period 2026-06-30 | 0001380106-26-000101 |
| 2026-08-07 | 07:02 ET | [8-K](/filings/0001380106-26-000097.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001380106-26-000097 |
| 2026-05-28 | 16:14 ET | [8-K](/filings/0001380106-26-000085.md) | 5.07 Shareholder vote results | 0001380106-26-000085 |
| 2026-05-19 | 17:13 ET | [8-K](/filings/0001104659-26-063936.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001104659-26-063936 |
| 2026-05-15 | 07:35 ET | [10-Q](/filings/0001380106-26-000075.md) | Quarterly report, period 2026-03-31 | 0001380106-26-000075 |
| 2026-05-13 | 16:33 ET | [8-K](/filings/0001380106-26-000067.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001380106-26-000067 |
| 2026-04-08 | 16:36 ET | [DEF 14A](/filings/0001380106-26-000057.md) | Proxy statement, period 2026-05-21 | 0001380106-26-000057 |
| 2026-03-27 | 16:34 ET | [8-K](/filings/0001380106-26-000045.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001380106-26-000045 |
| 2026-03-12 | 16:53 ET | [10-K](/filings/0001380106-26-000034.md) | Annual report, period 2025-12-31 | 0001380106-26-000034 |
| 2026-03-12 | 07:02 ET | [8-K](/filings/0001380106-26-000029.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001380106-26-000029 |
## Latest annual report
[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001380106-26-000034.md), filed Mar 12, 2026.
## Forecast league
Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/2c2a883e-8b36-4d4b-bd64-c388a65cff5f)
## About the filer
- CIK: 1380106
- Tickers: RPID
- Exchange: Nasdaq
- SIC code: 3826 Laboratory Analytical Instruments
- State of incorporation: DE
- Filer category: Non-accelerated filer
Smaller reporting company
Emerging growth company
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.